S&P 500   3,847.28 (-0.59%)
DOW   31,468.18 (+0.24%)
QQQ   311.92 (-2.04%)
AAPL   123.52 (-1.28%)
MSFT   229.21 (-1.99%)
FB   256.89 (-0.81%)
GOOGL   2,021.35 (-2.09%)
TSLA   678.37 (-1.18%)
AMZN   3,030.01 (-2.08%)
NVDA   518.92 (-3.23%)
BABA   236.65 (+0.95%)
CGC   33.76 (-4.23%)
GE   13.59 (+4.70%)
MU   91.21 (+0.13%)
NIO   42.64 (-1.50%)
AMD   82.17 (-2.33%)
T   28.54 (+1.13%)
F   12.37 (-1.43%)
ACB   10.62 (-3.72%)
DIS   194.58 (+0.33%)
BA   233.99 (+4.86%)
NFLX   524.45 (-4.27%)
PFE   34.22 (+2.12%)
S&P 500   3,847.28 (-0.59%)
DOW   31,468.18 (+0.24%)
QQQ   311.92 (-2.04%)
AAPL   123.52 (-1.28%)
MSFT   229.21 (-1.99%)
FB   256.89 (-0.81%)
GOOGL   2,021.35 (-2.09%)
TSLA   678.37 (-1.18%)
AMZN   3,030.01 (-2.08%)
NVDA   518.92 (-3.23%)
BABA   236.65 (+0.95%)
CGC   33.76 (-4.23%)
GE   13.59 (+4.70%)
MU   91.21 (+0.13%)
NIO   42.64 (-1.50%)
AMD   82.17 (-2.33%)
T   28.54 (+1.13%)
F   12.37 (-1.43%)
ACB   10.62 (-3.72%)
DIS   194.58 (+0.33%)
BA   233.99 (+4.86%)
NFLX   524.45 (-4.27%)
PFE   34.22 (+2.12%)
S&P 500   3,847.28 (-0.59%)
DOW   31,468.18 (+0.24%)
QQQ   311.92 (-2.04%)
AAPL   123.52 (-1.28%)
MSFT   229.21 (-1.99%)
FB   256.89 (-0.81%)
GOOGL   2,021.35 (-2.09%)
TSLA   678.37 (-1.18%)
AMZN   3,030.01 (-2.08%)
NVDA   518.92 (-3.23%)
BABA   236.65 (+0.95%)
CGC   33.76 (-4.23%)
GE   13.59 (+4.70%)
MU   91.21 (+0.13%)
NIO   42.64 (-1.50%)
AMD   82.17 (-2.33%)
T   28.54 (+1.13%)
F   12.37 (-1.43%)
ACB   10.62 (-3.72%)
DIS   194.58 (+0.33%)
BA   233.99 (+4.86%)
NFLX   524.45 (-4.27%)
PFE   34.22 (+2.12%)
S&P 500   3,847.28 (-0.59%)
DOW   31,468.18 (+0.24%)
QQQ   311.92 (-2.04%)
AAPL   123.52 (-1.28%)
MSFT   229.21 (-1.99%)
FB   256.89 (-0.81%)
GOOGL   2,021.35 (-2.09%)
TSLA   678.37 (-1.18%)
AMZN   3,030.01 (-2.08%)
NVDA   518.92 (-3.23%)
BABA   236.65 (+0.95%)
CGC   33.76 (-4.23%)
GE   13.59 (+4.70%)
MU   91.21 (+0.13%)
NIO   42.64 (-1.50%)
AMD   82.17 (-2.33%)
T   28.54 (+1.13%)
F   12.37 (-1.43%)
ACB   10.62 (-3.72%)
DIS   194.58 (+0.33%)
BA   233.99 (+4.86%)
NFLX   524.45 (-4.27%)
PFE   34.22 (+2.12%)
Log in
OTCMKTS:ENZN

Enzon Pharmaceuticals Stock Forecast, Price & News

$0.52
-0.02 (-3.73 %)
(As of 03/2/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.52
Now: $0.52
$0.61
50-Day Range
$0.30
MA: $0.54
$0.84
52-Week Range
$0.02
Now: $0.52
$0.85
Volume75,947 shs
Average Volume416,226 shs
Market Capitalization$38.27 million
P/E RatioN/A
Dividend YieldN/A
Beta0.77
Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in licensing drug products. Its marketed drug products include PegIntron and Sylatron. The company was founded in 1981 and is headquartered in Cranford, New Jersey.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolOTCMKTS:ENZN
Previous SymbolNASDAQ:ENZN
CUSIP29390410
Phone732-980-4500
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$210,000.00
Book Value$0.14 per share

Profitability

Net Income$-980,000.00
Net Margins-1,711.94%

Miscellaneous

Market Cap$38.27 million
Next Earnings Date3/3/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

0.56 out of 5 stars

Medical Sector

1422nd out of 1,969 stocks

Biological Products, Except Diagnostic Industry

159th out of 177 stocks

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$0.52
-0.02 (-3.73 %)
(As of 03/2/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ENZN News and Ratings via Email

Sign-up to receive the latest news and ratings for ENZN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Enzon Pharmaceuticals (OTCMKTS:ENZN) Frequently Asked Questions

What stocks does MarketBeat like better than Enzon Pharmaceuticals?

Wall Street analysts have given Enzon Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Enzon Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Enzon Pharmaceuticals?

Enzon Pharmaceuticals saw a decrease in short interest in February. As of February 12th, there was short interest totaling 2,600 shares, a decrease of 94.1% from the January 28th total of 44,400 shares. Based on an average daily trading volume, of 573,000 shares, the short-interest ratio is presently 0.0 days.
View Enzon Pharmaceuticals' Short Interest
.

When is Enzon Pharmaceuticals' next earnings date?

Enzon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, March 3rd 2021.
View our earnings forecast for Enzon Pharmaceuticals
.

How were Enzon Pharmaceuticals' earnings last quarter?

Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) released its quarterly earnings results on Thursday, April, 30th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter. Enzon Pharmaceuticals had a negative trailing twelve-month return on equity of 20.29% and a negative net margin of 1,711.94%.
View Enzon Pharmaceuticals' earnings history
.

How has Enzon Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Enzon Pharmaceuticals' stock was trading at $0.1693 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ENZN shares have increased by 204.6% and is now trading at $0.5157.
View which stocks have been most impacted by COVID-19
.

Who are Enzon Pharmaceuticals' key executives?

Enzon Pharmaceuticals' management team includes the following people:
  • Mr. Andrew Rackear J.D., CEO & Sec. (Age 67, Pay $173.51k)
  • Mr. Richard L. Feinstein, VP of Fin. & CFO (Age 78, Pay $160.88k)

Who are some of Enzon Pharmaceuticals' key competitors?

What other stocks do shareholders of Enzon Pharmaceuticals own?

What is Enzon Pharmaceuticals' stock symbol?

Enzon Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ENZN."

How do I buy shares of Enzon Pharmaceuticals?

Shares of ENZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enzon Pharmaceuticals' stock price today?

One share of ENZN stock can currently be purchased for approximately $0.52.

How much money does Enzon Pharmaceuticals make?

Enzon Pharmaceuticals has a market capitalization of $38.27 million and generates $210,000.00 in revenue each year.

What is Enzon Pharmaceuticals' official website?

The official website for Enzon Pharmaceuticals is www.enzon.com.

Where are Enzon Pharmaceuticals' headquarters?

Enzon Pharmaceuticals is headquartered at 20 Commerce Drive Suite 135, Cranford NJ, 07016.

How can I contact Enzon Pharmaceuticals?

Enzon Pharmaceuticals' mailing address is 20 Commerce Drive Suite 135, Cranford NJ, 07016. The biotechnology company can be reached via phone at 732-980-4500 or via email at [email protected]


This page was last updated on 3/3/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.